Replimune Group, Inc. SEC filings REPL
Replimune Group, Inc. has 657 filings in SEC EDGAR's recent list, going back to May 3, 2018. Its latest annual report, Form ARS, was filed on Jul 29, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Oct 28, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jul 29, 2026 | — |
| DEF 14A | Proxy statement | Jul 29, 2026 | Sep 15, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 13, 2026 | Sep 15, 2026 |
| DEFA14A | Additional proxy material | Jul 25, 2025 | — |
| DEF 14A | Proxy statement | Jul 25, 2025 | Sep 3, 2025 |
| DEFA14A | Additional proxy material | Jul 19, 2024 | — |
| DEF 14A | Proxy statement | Jul 19, 2024 | Sep 4, 2024 |
| DEFA14A | Additional proxy material | Jul 26, 2023 | — |
| DEF 14A | Proxy statement | Jul 26, 2023 | Sep 6, 2023 |
| DEFA14A | Additional proxy material | Jul 27, 2022 | — |
| DEF 14A | Proxy statement | Jul 27, 2022 | Sep 7, 2022 |
| DEFA14A | Additional proxy material | Jul 22, 2021 | — |
| DEF 14A | Proxy statement | Jul 22, 2021 | Sep 8, 2021 |
| DEF 14A | Proxy statement | Jul 29, 2020 | Sep 9, 2020 |
| DEF 14A | Proxy statement | Aug 9, 2019 | Sep 4, 2019 |
| PRE 14A | Preliminary proxy statement | Jul 29, 2019 | Sep 4, 2019 |
Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- REPL (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1737953
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.